Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
8
×
san diego blog main
san diego top stories
8
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
venture capital
8
×
wisconsin blog main
wisconsin top stories
boston top stories
cancer
fda
ipo
novartis
vc
biogen
celgene
gene editing
scott gottlieb
abbvie
amgen
clinical trials
What
bio
roundup
ipo
new
covid
fda
medicines
patients
years
abbvie’s
acquisitions
activity
advantages
ahead
allogene
announced
approvals
asco
bar
barbecuing
becker
billions
biogen
biopharma
branded
brings
camping
cancer
car
cardiologist
celgene
center
ceo
check
choices
cholesterol
clamped
collabs
colleagues
commissioner
Language
unset
Current search:
biotech
×
" venture capital "
×
" raleigh-durham top stories "
×
" san diego top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More